Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu

25 September 2026 · By · Wire by Fusion42

Published

25 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Elevar Therapeutics gained FDA approval for Lyrfigtu (lirafugratinib), an oral FGFR2 inhibitor for previously treated advanced cholangiocarcinoma with FGFR2 gene fusions or rearrangements, expanding targeted treatment options in the US.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 22 Sep 2026 and 25 Sep 2026.

◆ ◆ The Wire takeaway

You face a new regulatory green light to offer another FGFR2 inhibitor option for cholangiocarcinoma after Elevar’s FDA approval. Adjust your development or commercial plans accordingly to include lirafugratinib's entry and competitive dosing profile.

◆ Coverage

3 sources · first reported 22 Sep 2026 · latest 25 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalfgfr2cholangiocarcinomatargeted-therapy